Clinical relevance of serum interleukin-6 in Crohn's disease: Single point measurements, therapy monitoring, and prediction of clinical relapse

American Journal of Gastroenterology

Volumn 94, Issue 8, 1999, Pages 2156-2164

  Reinisch, Walter ^a  

^a Klinik fur Innere Medizin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; STEROID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SCORING SYSTEM;

EID: 0033179725     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1999.01288.x     Document Type: Article

References (64)

1. Hugot J-P, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996;379:821-3.
2. Sartor RB. Cytokines in intestinal inflammation: Pathophysiological and clinical considerations. Gastroenterology 1994; 106:533-9.
3. van Snick J. Interleukin-6: An overview. Annu Rev Immunol 1990;8:253-78.
4. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: Anti-inflammatory and immunosuppressive mediators. Immunol Today 1997;18:428-32.
5. Uyttenhove C, Coulie PG, van Snick J. T cell growth and differentiation induced by interleukin-HPl/IL-6, the murine hybridoma/plasmacytoma growth factor. J Exp Med 1988; 167:1417-27.
6. Takai Y, Wong GG, Clark S, et al. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol 1988;140:508-12.
7. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988;167:332-44.
8. Schindler R, Mancilla J, Endres S, et al. Correlation and interaction in the production of IL-6, IL-1 and TNF in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990;75:40-7.
9. Fattori E, Cappelletti M, Costa P, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994;180:1243-50.
10. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994:15:74-80.
11. Lotz M, Gueme P-A. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA). J Biol Chem 1990;266:2017-20.
12. Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113-8.
13. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993;77:1690-4.
14. Schürmann G, Betzier M, Post S, et al. Soluble interleukin-2 receptor, interleukin-6 and interleukin-1 beta in patients with Crohn's disease and ulcerative colitis: Preoperative levels and postoperative changes of serum concentrations. Digestion 1992;51:51-9.
15. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;! 19:771-8.
16. Leser HG, Gross V, Scheibenbogen C, et al. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 1991;101:782-5.
17. Byl B, Roucloux I, Crusiaux A, et al. Tumor necrosis factor alpha and interleukin-6 plasma levels in infected cirrhotic patients. Gastroenterology 1993:104:1492-7.
18. Madhok R, Crilly A, Watson J, et al. Serum interleukin-6 levels in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52:232-4.
19. van Gameren MM, Willemse PHB, Mulder NH, et al. Effects of recombinant human interleukin-6 in cancer patients: A phase MI study. Blood 1994;84:1434-41.
20. Nicken J, Mulder NH, Buter J, et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 1995:86:900-5.
21. Kusugami K, Fukatsu A, Tanimoto M, et al. Elevation of interleukin-6 in inflammatory bowel disease is macrophageand epithelial- cell-dependent. Dig Dis Sci 1995:40:949-59.
22. Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-alpha, interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39:684-9.
23. Reinecker H-C, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-lb by isolated lamina propria mononucïear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993:94:174-81.
24. Mazlam M, Hodgson H. Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut 1994;35:77-83.
25. Mahida Y, Kurlac L, Gallagher A, et al. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1991;32:1531-4.
26. Hyams JS, Fitzgerald JE, Treem WR, et al. Relatîbnship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993;104: 1285-92.
27. Gross V, Andus T, Caesar I, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992:102:514-9.
28. Lobo A, Evans S, Jones S, et al. Plasma interleukin-6 in inflammatory bowel disease. Eur J Gastroenterology Hepatology 1992;4:3367-72.
29. Holtkamp W, Stollberg T, Reis H. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. J Clin Gastroenterology 1995;20: 123-6.
30. Gasché C, Reinisch W, Lochs H, et al. Interleukin-6 production in Crohn's disease. Gastroenterology 1992;103:11201.
31. Montero-Julian FA, Klein B, Gautherot E, et al. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: Enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 1995:85:917-24.
32. Castell JV, Geiger T, Gross V, et al. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 1988;177:357-61.
33. May LT, Viquet H, Kenney JS, et al. High levels of complexed interleukin-6 in human blood. J Biol Chem 1992;267:19698704.
34. Hansen MB, Svenson M, Diamant M, et al. High affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 1993;5:72-80.
35. Pedersen MR, Jensen S, Christensen JD, et al. Lipopolysaccharide in concentrations above 40 ng/ml stimulates proliferation of the IL-6-dependent B9 cell line. J Immunol Methods 1995;180:159-63.
36. Chirmule N, Oyaizu N, Kalyanaraman VS, et al. Misinterpretation of results of cytokine bioassays. J Immunol Methods 1991;137:141-4.
37. Barton BE, Jackson JV, Lee F, et al. Oncostatin M stimulates proliferation in B9 hybridoma cells: Potential role of oncostatin M in plasmocytoma development. Cytokine 1994;6:14753.
38. Burger R, Gramatzki M. Responsiveness of the interleukin-6dependent cell line B9 to IL-11. J Immunol Methods 1993; 158:147-8.
39. Mackiewicz A, Schooltink H, Heinrich PC, et al. Complex of soluble human IL-6 receptor/IL-6 upregulates expression of acute-phase proteins. J Immunol 1992;149:2021-7.
40. Mitsuyama K, Toyonaga A, Sasaki E, et al. Soluble interleukin-6 receptors in inflammatory bowel disease: Relation to circulating interleukin-6. Gut 1995;36:45-9.
41. Hansen M, Svenson M, Diamant M, et al. Interleukin-6 (IL-6) autoantibodies and blood IL-6 measurements. Blood 1995;85: 1145.
42. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984;86:249-66.
43. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index-National Crohn's Disease Study. Gastroenterology 1976;70:439-44.
44. Schemper M. The relative importance of prognostic factors in studies of survival. Stat Med 1993;12:2377-82.
45. Armitage P, Berry G. Diagnostic tests and screening procedures. In: Armitage P, Berry G, eds. Statistical methods in medical research. Oxford, UK: Blackwell Scientific, 1994: 522-9.
46. Yoshimoto T, Nakanishi K, Hirose S, et al. High serum IL-6 level reflects susceptible status of the host to endotoxin and IL-1/tumor necrosis factor. J. Immunol 1992;148:396-403.
47. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996;10S2:81-90.
48. Mazlam MZ, Montazeri G, Hodgson HJF. The effects of some anti-inflammatory agents on cytokine release from human monocytes in vitro. Eur J Gastroenterology Hepatology 1993; 5:515-20.
49. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopie severity, and biological parame. ters in colonie or ilecolonic Crohn's disease. A prospective multicentre study of 121 cases. Gut 1994;35:231-5.
50. Singleton JW. Clinical activity assessment in inflammatory bowel disease. Dig Dis Sci 1987;32:42-5.
51. Lobo AJ, Sobala GM, Juby LD, et al. Evaluation of indices of disease activity in Crohn's disease by consensus analysis. Eur J Gastroenterology Hepatology 1991;3:663-6.
52. Lundqvist C, Baranov V, Hammarstrom S, et al. Intraepithelial lymphocytes. Evidence for regional specialization and extrathymic T cell maturation in the human gut epithelium. Int Immunol 1995;7:1473-87.
53. Mahida YR, Patel S, Gionchetti P, et al. Macrophage subpopulations in lamina propria of normal and inflamed colon and terminal ileum. Gut 1989;30:826-34.
54. Greenstein AJ, Lachmann P, Sachar DB, et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: Evidence for two clinical forms. Gut 1988;29:588-92.
55. Graham MF, Diegelmann RF, Elson CO, et al. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology 1988;94:257-65.
56. Greenstein RJ. Crohn's disease: To lump or to split? Gastroenterology 1995;109:2045-6.
57. Graham MF, Willey A, Adams J, et al. Interleukin-lß downregulates collagen and augments collagenase expression in human intestinal smooth muscle cells. Gastroenterology 1996; 110:344-50.
58. Gilberts ECAM, Greenstein AJ, Katsel P, et al. Molecular evidence for two forms of Crohn's disease. Proc Natl Acad Sci USA 1994;91:12721-4.
59. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1-beta in relapse of Crohn's disease. Lancet 1999;353:459-61.
60. Louis E, Belaiche J, Van Kemseke C, et al. Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse. Dig Dis Sci 1995;40:1750-6.
61. Brignola C, Campieri M, Bazzocchi G, et al. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986;91:1490-4.
62. Wyatt J, Vogelsang H, Hübl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993; 341:1437-9.
63. Louis E, Belaiche J, van Kemseke C, et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol 1997;9: 939-44..
64. Reinisch W, Gasché C, Wyatt J, et al. Steroid dependency in Crohn's disease. Lancet 1995;345:859.